Aurobindo Pharma
₹1,677
- Market Cap
- ₹95,626Cr.
- P/E Ratio
- 25.3
- P/B Ratio
- 2.57
- EPS (TTM)
- ₹66.28
- Div Yield
- 0.24%
- ROCE
- 12.9%
- ROE
- 10.1%
52W Low: ₹1,08052W High: ₹1,740
Themes:💊 Pharma & CDMO
Appears in 1 screen
Descriptive screens built from published data — not investment advice.
At a glance
- Sales have grown 11.0% a year over three years.
- Debt is 0.21× its shareholders’ equity.
From reported financials and exchange prices. Descriptive only, not advice.
Aurobindo_Pharma — Price
Interval
Style
Failed: 503
Evenstocks Score
Middle third
Overall
Valuation
Quality
Fundamental
Growth
Investment Checklist
Quick assessment based on key parametersPerformance
N/ATrailing return unavailableValuation
P/E 25.3P/E: 25.3 | P/B: 2.57Growth
GrowingSales CAGR — 3Y: 11% · 1Y: 9%Profitability
ModerateROCE: 12.9% | ROE: 10.1%Key Metrics
Valuation
PEG Ratio 1.10
Price / Sales 2.74x
Price / FCF 38.8x
Book Value ₹652
Margins & returns
Operating Margin 20%
Net Margin 10.6%
Return on Assets 6.4%